Piroon Mootsikapun

Dr. Piroon Mootsikapun


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
PMPiroon Mootsikapun
Piroon Mootsikapun
BIBenjamas Intarapoka
Benjamas Intarapoka
WLWaraporn Liawnoraset
Waraporn Liawnoraset

1 January 2006 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
PMPiroon Mootsikapun
Piroon Mootsikapun
SSSukanya Srikulbutr
Sukanya Srikulbutr

1 May 2007 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
PMPiroon Mootsikapun
Piroon Mootsikapun

15 May 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPiroon Mootsikapun
Piroon Mootsikapun
PHPo-Ren Hsueh
Po-Ren Hsueh
DTDeepak Talwar
Deepak Talwar
VCVilma M Co
Vilma M Co
VRViraj Rajadhyaksha
Viraj Rajadhyaksha
MOMoh-Lim Ong
Moh-Lim Ong
Candidemia is a significant cause of morbidity and mortality in hospitalized patients, particularly in Asia. Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different. An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. Treatment was initiated with intravenous anidulafungin, given for at least 5 days, with the option to complete treatment with oral voriconazole. The primary endpoint was global (clinical and microbiological) response, and the primary analysis was the proportion of patients in the modified intent-to-treat population with successful global response at the end of therapy. Secondary analyses included proportion with successful global response in clinically relevant patient subgroups. The safety and tolerability profile of anidulafungin and voriconazole in this population was also investigated. Forty-three patients were studied, including 42 in the modified intent-to-treat population. Eighteen patients were > 65 years, the largest age subgroup, and 21 had central venous catheters. The most common Candida species causing infection were C. tropicalis (n = 18) and C. albicans (n = 10). In the primary analysis, 73.8% had a successful global response at end of therapy. Success rates in subgroups were: 72.2% for C. tropicalis and 71.4% for C. albicans infection, 58.8% for patients > 65 years, and 81.0% for patients with central venous catheters. Safety and tolerability were comparable with the known profiles for anidulafungin (and voriconazole). Although the epidemiology of Candida infections was different in this open-label study, the efficacy of anidulafungin in Asian patients with documented candidemia was consistent with previous studies in Western populations. No new safety concerns were identified. http://www.clinicaltrials.gov identifier NCT00537329

13 September 2012 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
PKPiyatip Khuntayaporn
Piyatip Khuntayaporn
PMPreecha Montakantikul
Preecha Montakantikul
PMPiroon Mootsikapun
Piroon Mootsikapun
VTVisanu Thamlikitkul
Visanu Thamlikitkul
MCMullika Chomnawang
Mullika Chomnawang
Background: Increased infection caused by multidrug resistant (MDR) Pseudomonas aeruginosa has raised awareness of the resistance situation worldwide. Carbapenem resistance among MDR (CR-MDR) P. aeruginosa has become a serious life-threatening problem due to the limited therapeutic options. Therefore, the objectives of this study were to determine the prevalence, the antibiotic susceptibility patterns and the relatedness of CR-MDR P. aeruginosa in tertiary hospitals across Thailand. Methods: MDR P. aeruginosa from eight tertiary hospitals across Thailand were collected from 2007–2009. Susceptibility of P. aeruginosa clinical isolates was determined according to the Clinical and Laboratory Standards Institute guideline. Selected CR-MDR P. aeruginosa isolates were genetically analyzed by pulsed-field gel electrophoresis. Results: About 261 clinical isolates were identified as MDR P. aeruginosa and approximately 71.65% were found to be CR-MDR P. aeruginosa. The result showed that the meropenem resistance rate was the highest reaching over 50% in every hospitals. Additionally, the type of hospitals was a major factor affecting the resistance rate, as demonstrated by significantly higher CR-MDR rates among university and regional hospitals. The fingerprinting map identified 107 clones with at least 95% similarity. Only 4 clones were detected in more than one hospital. Conclusions: Although the antibiotic resistance rate was high, the spreading of CR-MDR was found locally. Specific strains of CR-MDR did not commonly spread from one hospital to another. Importantly, clonal dissemination ratio indicated limited intra-hospital transmission in Thailand.

1 December 2008
Verified
Journal Article
Closed access
SSSomnuek Sungkanuparph
Somnuek Sungkanuparph
TAThanomsak Anekthananon
Thanomsak Anekthananon
NHNarin Hiransuthikul
Narin Hiransuthikul
CBChureeratana Bowonwatanuwong
Chureeratana Bowonwatanuwong
KSKhuanchai Supparatpinyo
Khuanchai Supparatpinyo
KRKiat Ruxrungtham
Kiat Ruxrungtham